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Objective: Widespread use of self-expanding nitinol stent-based endovascular treatment (EVT) for femoropopliteal (FP)
lesions has been fueled by its less-invasive nature and modest durability; however, prevalence, predictors and prognosis of
in-stent occlusion are undeﬁned and were investigated here.
Methods: This study entailed a multicenter, retrospective analysis of a prospectively maintained database. Between January
2004 and December 2011, 2447 de novo FP lesions (mean length, 143 6 87 mm; 52% chronic total occlusions) from
2008 patients (mean age, 73.06 9.2 years; 71% male; 61% diabetics; 32% critical limb ischemia; and 24% on hemodialysis)
were treated with nitinol stent-based EVT. Study outcome was in-stent occlusion: rates (1, 3, and 5 years), predictors and
association with limb prognosis.
Results: In-stent occlusion rate was 5.2%, 11.2%, and 16.4% at 1, 3, and 5 years, respectively (mean follow-up, 2.3 6
1.7 years). Female sex, critical limb ischemia, and Transatlantic Inter-Society Consensus II class C/D (multivariate Cox
proportional hazard ratio [HR], 1.75, 1.49, and 3.34, respectively) were independent predictors of in-stent occlusion
after FP stenting, which was associated with poor limb prognosis (major amputation, HR 6.35; major adverse limb event,
major adverse limb event, HR, 21.1).
Conclusions:Moderate in-stent occlusion rates were observed after nitinol stent-based EVT. Closer attention is warranted
with high-risk cases because of poorer limb prognosis. (J Vasc Surg 2014;59:1009-15.)Improved outcomes underlie recent guidelines and
broader use of endovascular therapy (EVT) for femoro-
popliteal (FP) artery disease with nitinol stents.1,2
However, the 30% 1-year in-stent restenosis rate remains
a clinical challenge for which there is no standard
therapy.3-7 In particular, in-stent occlusion has been associ-
ated with poor outcomes after target lesion revasculariza-
tion with standard balloon angioplasty. Tosaka et al
reported that freedom from recurrent in-stent restenosis
after balloon angioplasty for in-stent occlusion was much
lower than that for in-stent restenosis.8 Similarly, anotherthe Advanced Cardiovascular Therapeutics, Osaka University Grad-
te School of Medicine, Suitaa; the Kansai Rosai Hospital Cardiovascular
enter, Amagasakib; the Department of Cardiology, Kokura Memorial
ospital, Kitakyusyuc; the Department of Cardiology, Saiseikai Yoko-
ma-city Eastern Hospital, Yokohamad; the Department of Cardiology,
ndai Kosei Hospital, Sendaie; and the Department of Metabolic Medi-
ne, Osaka University Graduate School of Medicine, Suita.f
or conﬂict of interest: none.
ented during the International Forum of the 2013 Vascular Annual
eeting of the Society for Vascular Surgery, San Francisco, Calif, May
-June 1, 2013.
itional material for this article may be found online at www.jvascsurg.org.
rint requests: Tomoharu Dohi, MD, Kansai Rosai Hospital Cardiovas-
lar Center, 3-1-69 Inabaso, Amagasaki, Hyogo 660-8511, Japan
-mail: tomoharu.dohi@gmail.com).
editors and reviewers of this article have no relevant ﬁnancial relationships
disclose per the JVS policy that requires reviewers to decline review of any
anuscript for which they may have a conﬂict of interest.
-5214/$36.00
yright  2014 by the Society for Vascular Surgery.
://dx.doi.org/10.1016/j.jvs.2013.10.050report suggested that in-stent occlusion was associated
with a signiﬁcantly higher risk of restenosis and reocclusion
following second intervention.9 Nonetheless, the rate,
predictors, and impact on limb prognosis of in-stent occlu-
sion after EVT with FP stenting has not been systematically
studied and are the subject of this study.
METHODS
Study design. This study is a subgroup analysis of the
femoropopliteal stenting (Retrospective Multicenter Anal-
ysis for Femoropopliteal Stenting [REAL-FP]) registry,
which is registered with the university hospital medical
information network-clinical trials registry (No. UMIN
000010986). REAL-FP was a nonrandomized multicenter
clinical trial conducted at 13 sites in Japan. The study was
approved by the institutional review boards at all partici-
pating institutions.
Study participants. The study patient ﬂow is shown in
Fig 1. Between January 2004 and December 2011, 5679
limbs from 4697 consecutive patients identiﬁed with FP
lesions at each hospital underwent EVT. Of these cases,
2056 limbs were excluded because of restenotic lesions,
history of previous revascularization of the FP artery by
EVT, or bypass surgery, acute onset limb ischemia, or for
other reasons. As a result, 3623 limbs from 2911 patients
with de novo FP lesions were analyzed in the REAL-FP
registry. This study further excluded 152 failed limbs,
951 limbs treated with angioplasty alone and 73 limbs
treated with stainless-steel stents. Therefore, 2447
limbs (2008 patients) underwent successful EVT with1009
Fig 1. Patient ﬂow diagram. EVT, Endovascular treatment; FP, femoropopliteal.
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this study. A total of 1377 patients underwent bypass at
participating institutions during the same time periods.
Endovascular procedure and follow-up. Endovascu-
lar procedures were performed through an antegrade and/
or retrograde approach. An antegrade or retrograde guide-
wire was selected from a hydrophilic 0.035-inch Radio-
focus (Terumo, Tokyo) or 0.018- or 0.014-inch guidewire
for peripheral intervention, and advanced to the lesions.
After the guidewire crossed the lesion, in 675 limbs (28%),
intravascular ultrasound was used to conﬁrm that the
guidewire was in the lumen. In these cases, intravascular
ultrasound was also used to precisely estimate vessel
diameters, the degree of dissection, and stent expansion.
Provisional stenting was performed with self-expanding
nitinol stents, which were chosen at physicians’ discre-
tion: SMART (Cordis Corporation, Miami Lakes, Fla),
Luminexx (Bard Inc, Murray Hill, NJ), Zilver (Cook
Medical, Bloomington, Ill), or Misago (Terumo, Tokyo,
Japan). In general, stent length was determined so as to
cover the entire lesion, and stent size was chosen to be 1 or
2 mm larger than reference vessel diameter. About 1 cm of
overlap was used for multiple stents. Poststent angioplasty
was performed in all stented cases. In almost all cases with
coexisting proximal or distal lesions to the treatment
section (ie, aorto-iliac or below-the-knee lesions), the latterlesions were treated simultaneously or within a week. The
number of runoff vessels was assessed by digital subtraction
angiography immediately after treatment. After the
procedure, all patients were prescribed life-long aspirin
(100 mg/d), and prolonged (at least 1 month) clopidogrel
75 mg/d or ticlopidine 200 mg/d was recommended.
Patients on cilostazol (100 or 200 mg/d) before the
procedure continued to receive it after the procedure.
During the procedure, unfractionated heparin was injected
intra-arterially to maintain the active clotting time at
>200 seconds. Resting ankle brachial index, Rutherford
class, stent fracture, and duplex ultrasound of the stented
vessel were routinely monitored within 30 days and every
6 months thereafter in concert with clinical examinations.
Repeated revascularization was performed based on clinical
symptoms with greater than 50% restenosis assessed by
duplex ultrasound or angiography.
Study outcomes and deﬁnitions. Study outcomes
comprised the incidence, predictors, and prognosis of in-
stent occlusion after FP stenting. In this study, one limb
had only one lesion. Hence, two separate lesions in one
limb were considered as one lesion, and one patient could
at most have two lesions. In-stent occlusion was deﬁned
as any occlusion after index procedure, including those
after secondary interventions. In-stent occlusion was deter-
mined by duplex ultrasound or angiography and deﬁned as
Table I. Patient characteristics
No. (%) or mean 6 SD
Age, years 73.0 6 9.2
Male 1420 (71)
BMI 22.2 6 3.4
Nonambulatory 288 (14)
Rutherford classiﬁcation
II 439 (22)
III 855 (43)
IV 193 (10)
VI 346 (17)
VI 94 (5)
CLI 633 (32)
Comorbidity
Hypertension 1714 (85)
Hyperlipidemia 1006 (50)
Diabetes 1222 (61)
CAD 1010 (50)
CVD 442 (22)
Hemodialysis 478 (24)
Current smoking 524 (26)
Medication
Aspirin 1757 (88)
Thienopyridines 1016 (51)
Cilostazol 1008 (50)
Warfarin 248 (12)
Statins 775 (39)
BMI, Body mass index; CAD, coronary artery disease; CLI, critical limb
ischemia; CVD, cerebrovascular disease; SD, standard deviation.
Table II. Lesion characteristics
No. (%) or mean 6 SD
Lesion length 142.5 6 87.6
Reference vessel diameter 5.3 6 0.9
Chronic total occlusion 1283 (52)
Calciﬁed lesion 1391 (57)
ABI before procedure 0.61 6 0.21
ABI after procedure 0.89 6 0.17
Number of BTK run-off
0 205 (8)
1 824 (34)
2 777 (32)
3 454 (19)
Number of stent 1.9 6 0.9
Stent size used 6.8 6 0.9
Multiple stents 1405 (57)
Type of nitinol stent
SMART 1858 (76)
Luminexx 307 (13)
Zilver 191 (8)
Misago 41 (2)
Combined 48 (2)
Stent fracture 106 (4.3)
TASC II class
A 580 (24)
B 637 (26)
C 418 (17)
D 812 (33)
ABI, Ankle brachial index; BTK, below the knee; SD, standard deviation;
TASC, TransAtlantic Inter-Society Consensus.
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predictors of in-stent occlusion after FP stenting were
analyzed by multivariate analysis. In addition, prognosis
after in-stent occlusion was assessed as major amputation,
which was deﬁned as above-the-ankle amputation, and
major adverse limb event (MALE), which was deﬁned as
major amputation or major reintervention including any
surgical procedure such as bypass, arterectomy, or throm-
bectomy. Greater than 50% stenosis was evaluated by
duplex ultrasound or angiography, and deﬁned as peak
systolic velocity ratio >2.4 by duplex or >50% stenosis by
quantitative vascular analysis.
Statistical analysis. Statistical analysis was done with
SPSS v. 20 (SPSS Inc, Chicago, Ill). Continuous variables
are expressed as mean 6 standard deviation. The incidence
of in-stent occlusion was estimated by the Kaplan-Meier
method. Cox proportional hazard analysis was performed
to determine the association of baseline characteristics with
in-stent occlusion. First, age, sex, ambulatory status,
current smoking, hypertension, hyperlipidemia, diabetes,
hemodialysis, critical limb ischemia (CLI), and Trans-
Atlantic Inter-Society Consensus (TASC) II classiﬁcation
were chosen as variables. Variables that were signiﬁcant in
the univariate model were entered into the multivariate
model to examine for independent associations. In addi-
tion, the association of in-stent occlusion with future limb
prognosis (ie, major amputation and MALE) was investi-
gated by Cox hazard regression analysis with in-stent
occlusion as a time-dependent covariate. A P value
of <.05 was considered statistically signiﬁcant.RESULTS
Baseline characteristics. In this study, data on 2008
patients with 2447 limbs were extracted from the REAL-
FP registry. The clinical follow-up rate was 70% (1710
limbs) at 1 year, 42% (1033 limbs) at 2 years, 25% (606
limbs) at 3 years, 16% (382 limbs) at 4 years, and 7.6%
(187 limbs) at 5 years, respectively. Baseline characteristics
are listed in Tables I and II. Mean age was 73.0 6
9.2 years, and 71% of patients were male. Nonambulatory
status was observed in 14% (288 patients) of cases. The
percentage of patients with intermittent claudication and
CLI was 68% and 32%, respectively. Sixty-one percent of
patients had diabetes and 24% were on hemodialysis.
Antiplatelet therapy use at the time of treatment was as
follows: aspirin (1757 patients, 88%), and thienopyridines
(1016 patients, 51%) or warfarin (248 patients, 12%).
Mean lesion length was 142.5 6 87.2 mm and reference
vessel diameter was 5.3 6 0.9 mm. Fifty-two percent of
lesions were chronic total occlusions and 57% had calciﬁ-
cation. Number of stents per limb was 1.9 6 0.9. Stent
fracture was observed in 106 limbs (4.3%). By TASC II
classiﬁcation, 580 limbs (23.7%), 637 limbs (26.0%), 418
limbs (17.1%), and 812 limbs (33.2%) were in classes A, B,
C, and D, respectively.
Outcome measures. In a treated limb-based analysis,
the mean follow-up period was 2.3 6 1.7 years. In-stent
occlusion was found in 201 of 2447 treated limbs (8.2%)
during the observational period. In-stent occlusion rate was
estimated to be 5.2%, 11.2%, and 16.4% at 1, 3, and
Fig 2. Cumulative 5-year rate of in-stent occlusion in 2447 limbs after femoropopliteal stenting with self-expanding
nitinol stents. The cumulative rate of in-stent occlusion is depicted as a Kaplan-Meier curve. SE, Standard error.
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Of these limbs, one was treated with femoropopliteal
bypass, 25 with continued monitoring, six of which resul-
ted in major amputation, and 175 with angioplasty alone.
After angioplasty, 24 limbs were converted to bypass
surgery, and subsequently one of these cases underwent
major amputation. Furthermore, one case without bypass
surgery resulted in failed limb salvage (Fig 3).
The predictors of in-stent occlusion are shown in
Table III. Multivariate Cox proportional hazard analysis
showed that female sex (hazard ratio [HR], 1.75; 95%
conﬁdence interval [CI], 1.31-2.32; P < .05), CLI (HR,
1.49; 95% CI, 1.10-2.02; P < .001), and TASC II C/D
(HR, 3.34; 95% CI, 2.41-4.62; P < .001) were indepen-
dent predictors of in-stent occlusion. Neither antiplatelet
therapy nor warfarin appeared to have a protective effect
on in-stent occlusion. Reference vessel diameter and stent
size used were signiﬁcant in the univariate model, but did
not change analysis results when included in the multivar-
iate model.
We also performed a Cox hazard regression analysis in
which in-stent occlusion was treated as a time-dependent
covariate to assess its association with future limb prognosis
(ie, major amputation and MALE). The result is shown in
Table IV. Limbs with in-stent occlusion had a signiﬁcantly
increased risk for major amputation (adjusted HR, 6.35;
95% CI, 2.74-14.7; P < .0001) and MALE (adjusted
HR, 21.1; 95% CI, 12.5-35.7; P < .0001) when adjust-
ments were made for age, sex, CLI, TASC II classiﬁcation,
ambulatory status, smoking, hypertension, hyperlipidemia,diabetes, and hemodialysis. The overall cumulative inci-
dence of major amputation was 1.9%, 3.1%, and 3.5%,
and that of MALE was 3.2%, 5.1%, and 6.6%, at 1, 3,
and 5 years, respectively.
The rates of in-stent occlusion at 5 years among stents
were SMART (Cordis Corporation) 13.5%, Luminexx
(Bard Inc) 26.1%, Zilver 17.1%, and Misago (Terumo)
2.9% (up to 2 years), respectively. A signiﬁcant difference
was observed only between SMART and Luminexx
(Supplementary Fig, online only). In an analysis for major
amputation and MALE, controlling for stent type used
and the result did not differ (log-rank test, major amputa-
tion: P ¼ .685; MALE: P ¼ .805).DISCUSSION
This study had a unique primary end point. Although
primary or secondary patency usually is determined as
a main end point, there is a sizable number of repeat angio-
plasty cases with every in-stent occlusion that result in
bypass conversion or otherwise major amputation in clin-
ical settings. In addition, our group previously reported
that in-stent occlusion has been associated with poor
outcomes after target lesion revascularization with standard
balloon angioplasty.8 Nonetheless, the incidence, predic-
tors, and impact on limb prognosis of in-stent occlusion
after EVT with FP stenting have not been systematically
studied. Therefore, this study was designed considering
experience in real clinical settings and focused on in-stent
occlusion.
Fig 3. Outcomes after in-stent occlusion during the study period.
Table III. Association of baseline characteristics with in-stent occlusion
Unadjusted
HR (95% CI)
(Crude model)
Adjusted HR
(95% CI)
(Model 1)
Adjusted HR
(95% CI)
(Model 2)
Adjusted HR
(95% CI)
(Model 3)
Adjusted HR
(95% CI)
(Model 4)
Female 1.91 (1.45-2.53)a 1.75 (1.31-2.32)a 1.73 (1.30-2.30)a 1.63 (1.22-2.17)a 1.61 (1.21-2.15)a
Age-years 1.00 (0.99-1.02) - - - -
Nonambulatory 1.38 (0.89-2.14) - - - -
Current smoking 1.12 (0.83-1.52) - - - -
Hypertension 1.16 (0.75-1.79) - - - -
Hyperlipidemia 0.98 (0.74-1.29) - - - -
Diabetes 0.78 (0.59-1.03) - - - -
Hemodialysis 0.91 (0.64-1.29) - - - -
CLI 1.76 (1.31-2.37)b 1.49 (1.10-2.02)b 1.50 (1.11-2.04)b 1.50 (1.11-2.03)b 1.50 (1.11-2.04)b
TASC C/D 3.46 (2.50-4.78)b 3.34 (2.41-4.62)b 3.35 (2.42-4.63)b 3.29 (2.37-4.55)b 3.30 (2.38-4.56)b
Aspirin 0.90 (0.59-1.37) - 0.99 (0.65-1.51) - 0.96 (0.63-1.47)
Thienopyridine 0.93 (0.74-1.31) - 0.97 (0.73-1.30) - 0.94 (0.70-1.25)
Wafarin 0.82 (0.50-1.36) - 0.81 (0.49-1.34) - 0.82 (0.50-1.35)
Reference vessel diameter 0.78 (0.66-0.93)b - - 0.90 (0.75-1.08) 0.89 (0.74-1.07)
Stent size used 0.78 (0.66-0.92)b - - 0.85 (0.70-1.02) 0.85 (0.71-1.02)
CI, Conﬁdence interval; CLI, critical limb ischemia; HR, hazard ratio; TASC, TransAtlantic Inter-Society Consensus.
Model 1, Adjusted for sex, CLI, and TASC classiﬁcation; Model 2, adjusted for sex, CLI, TASC classiﬁcation, aspirin, thienopyridines, and warfarin; Model 3,
adjusted for age, sex, CLI, TASC classiﬁcation, reference vessel diameter, and stent size used; Model 4, adjusted for age, sex, CLI, TASC classiﬁcation, aspirin,
thienopyridines, warfarin, reference vessel diameter, and stent size used.
aP < .05.
bP < .001.
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Stenting With Nitinol Stents in the Superﬁcial Femoral
Artery) trial, in-stent occlusion rate was 12% at 1 year4;
in another study, it was 3.5% for SMART stent group
and 8.1% for Luminexx group,10 whereas in another report
it reached 22%.11 These studies had a small number of
subjects and short follow-up periods. In contrast, this study
had a larger number of subjects and longer follow-up
(up to >5 years) rendering more informative than previous
reports.In this study, in-stent occlusion was signiﬁcantly asso-
ciated with poor limb prognosis. Some previous reports
have suggested that stent failure including in-stent occlu-
sion was associated with subsequently worsening runoff,
especially among limbs initially classiﬁed as TASC C or D,
and also negatively affect limb prognosis.12,13 The status
of runoff at the time of in-stent occlusion was not avail-
able in this study, and further investigation is needed to
assess a causal connection between in-stent occlusion and
limb prognosis.
Table IV. Association of in-stent occlusion with future limb prognosis
Unadjusted HR
(95% CI)
Adjusted HR
(95% CI)
Adjusted HR
(95% CI)
Adjusted HR
(95% CI)
(Crude model) (Model 1) (Model 2) (Model 3)
Risk of major amputation 7.33 (3.30-16.3) 6.85 (3.06-15.3) 4.37 (1.95-9.82) 6.35 (2.74-14.7)
P < .001 P < .001 P < .001 P < .001
Risk of MALE 21.0 (12.9-34.3) 19.9 (12.2-32.7) 15.1 (9.25-24.6) 21.1 (12.5-35.7)
P < .001 P < .001 P < .001 P < .001
CI, Conﬁdence interval; HR, hazard ratio; MALE, major adverse limb event.
Model 1, Adjusted for age and sex; Model 2, adjusted for age, sex, CLI, and TASC classiﬁcation; Model 3, adjusted for age, sex, CLI, TASC classiﬁcation,
ambulatory status, smoking, hypertension, hyperlipidemia, diabetes, and hemodialysis.
The overall cumulative incidence of major amputation was 1.9%, 3.1%, and 3.5%, and that of MALE was 3.2%, 5.1%, and 6.6%, at 1, 3, and 5 years, respectively.
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identiﬁed as risk factors for in-stent occlusion. All of these
factors have been reported to be associated with poor
outcomes such as restenosis.14-17 In particular, TASC II
C/D has been signiﬁcantly associated with poor outcomes
in this and many studies.16,17 TASC II C/D is a complex
lesion (ie, longer, occlusive, and involving the popliteal
artery). Therefore, the risk of stent failuremight be increased
such as is in multiple stenting or, stent fracture.18-20 Further
studies are needed to conﬁrm this ﬁnding.
There is a possibility of involvement of thrombus in in-
stent occlusion, and therefore, antiplatelet therapy use was
assessed as possible protective factor. However, this study
failed to reveal effectiveness of antiplatelet therapy for
prevention of in-stent occlusion maybe because status of
antiplatelet therapy use could be obtained only at the
time of treatment and it was unknown if it had been
continued or not. A meta-analysis had provided limited
evidence,21 and further study on the effect of each drug
on in-stent occlusion is needed.
Although EVT with nitinol stent has been predomi-
nantly used in the treatment of FP lesions, the incidence,
prognosis, and predictors of in-stent occlusion have not
been investigated using a large dataset. According to the
results of this study, in-stent occlusion rate was low suggest-
ing that EVT with nitinol stents is effective and feasible in
the treatment of FP lesions. Prognosis after in-stent occlu-
sion was however signiﬁcantly poorer than in its absence.
Although currently, bypass surgery appears to remain the
ﬁrst-line option for in-stent occlusion treatment, in the
near future, new devices such as atherectomy devices,
drug-eluting stents, drug-coating balloons, or their combi-
nation are expected to provide better alternatives.22-25
Limitations. There are several limitations in this study.
First, this study was a retrospective, nonrandomized
analysis, despite being a large-scale multicenter study.
Second, lesion length, reference vessel diameter, runoff
score, or stent fractures were not strictly assessed by core
laboratory evaluation. Therefore, these were likely to be
over- or underestimated. In particular, stent fracture rate
was much lower than in a previous study likely because it was
underestimated, except for major fracture, particularly
among patent cases. In all in-stent occlusion cases, however,
radiography was performed and, therefore, the impact ofstent fracture was likely to be small. Third, the selection of
stent (brand, size, and overlap length) was left to physician’s
discretion. Finally, status of antiplatelet therapy use at the
time of in-stent occlusion and details on all secondary
interventions were not recorded. Despite these limitations,
the ﬁndings in this study are expected to closely reﬂect the
effect of in-stent occlusion in the clinical setting.
CONCLUSIONS
EVT with nitinol stents for FP lesions appears effective
with relative low rates of in-stent occlusion. Female sex,
CLI, and TASC II C/D were the predictors of in-stent
occlusion, which in turn were independent predictors of
poor limb prognosis.
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Supplementary Fig (online only). Cumulative 5-year rate of in-stent occlusion among stent manufacturers.
A signiﬁcant difference was observed only between SMART and Luminexx.
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